Align Technology Inc header image

Align Technology Inc

ALGN

Equity

ISIN null / Valor 1159441

NASDAQ (2025-11-21)
USD 142.56+7.34%

Align Technology Inc
UMushroom community rating:

star star star star star
4.50 2 votes No rating yet
NegativeNeutralPositive

About company

Align Technology Inc is a global leader in the dental CAD/CAM software market, offering fully integrated workflows to dental labs and practices through a wide network of partners and resellers in over 150 countries. The company's digital scanning technology, including the iTero intraoral scanner, complements its Invisalign system, enhancing patient scans and overall experience. Align Technology continues to invest in digital restorative workflows, with over 17 million restorative cases enabled by the iTero scanner to date. Additionally, the company provides a range of digitally enabled solutions for restorative dentistry, orthodontic treatment, and other dental applications. With a focus on innovation and customer satisfaction, Align Technology remains a leading provider of advanced clear aligner systems and digital orthodontic solutions worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (11.11.2025):

In Q3 2025, Align Technology Inc reported a solid financial performance with total revenues of $995.7 million – up 1.8% year-over-year but down 1.7% sequentially – driven largely by a strong performance in its Clear Aligner segment and favorable foreign exchange impacts. The quarter saw clear aligner volumes grow, particularly among teens and kids, while operating income reached $96.3 million with a GAAP margin of 9.7% and a non-GAAP margin of 23.9%. Additionally, the company increased its cash position and executed strategic share repurchases despite headwinds in its imaging systems segment and restructuring-related charges.

Total Revenues & Margins

For Q3 2025, Align Technology Inc recorded total revenues of $995.7 million, reflecting a 1.8% increase year-over-year and a 1.7% sequential decline. Operating income was reported at $96.3 million, with a GAAP operating margin of 9.7% and a non-GAAP margin of 23.9%, benefiting from favorable foreign exchange adjustments.

Clear Aligner Performance

The Clear Aligner segment delivered strong results with revenues of $805.8 million, up 2.4% year-over-year and 0.1% sequentially. Total clear aligner volume reached 647.8 thousand cases (up 4.9% year-over-year and 0.5% sequentially), with the teens and kids segment showing particularly robust growth at 8.3% year-over-year and 14.7% sequentially to 256.0 thousand cases.

Imaging Systems & CAD/CAM Services

Revenues from Imaging Systems and CAD/CAM Services were $189.9 million, experiencing a slight decline of 0.6% year-over-year and an 8.6% sequential drop, mainly attributed to typical Q3 capital equipment seasonality.

Cash Position & Stock Repurchases

Align Technology Inc reinforced its balance sheet with cash and cash equivalents of $1,004.6 million, up from $901.2 million in Q2 2025. The company also repurchased approximately 0.5 million shares at an average price of $136.77, under its $200.0 million open market repurchase plan.

Restructuring & Other Charges

Q3 2025 included restructuring, impairment, and accelerated depreciation charges totaling $88.3 million, which, alongside other non-cash charges, impacted the overall operating performance for the quarter.

Summarized from source with an LLMView Source

Key figures

-37.5%1Y
-25.6%3Y
-68.1%5Y

Performance

60.3%1Y
51.9%3Y
51.3%5Y

Volatility

Market cap

10229 M

Market cap (USD)

Daily traded volume (Shares)

1,814,117

Daily traded volume (Shares)

1 day high/low

208.1 / 204.16

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.50

2 votes
Performance:
starstarstarstarstar
4.50
Innovation:
starstarstarstarstar
4.00
Society:
starstarstarstarstar
4.50
Nature:
starstarstarstarstar
4.00
Luba Schoenig
Switzerland, 29 May 2024
star star star star star
The market value of the dental aligners is set for fast growth
Lea Katunaric
Switzerland, 28 May 2024
star star star star star
Seems to be gaining interest and relevance as a beauty stock. I would keep an eye on it.

EQUITIES OF THE SAME SECTOR

Straumann Holding Ltd
Straumann Holding Ltd Straumann Holding Ltd Valor: 117544866
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.30%CHF 96.58
National Healthcare Corp
National Healthcare Corp National Healthcare Corp Valor: 836282
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.42%USD 130.44
Maternus-Kliniken AG
Maternus-Kliniken AG Maternus-Kliniken AG Valor: 335800
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.94%EUR 1.05
Dyne Therapeutics Inc
Dyne Therapeutics Inc Dyne Therapeutics Inc Valor: 56806425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.27%USD 21.18
Boiron SA
Boiron SA Boiron SA Valor: 487646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.95%EUR 26.60
Baxter International Inc
Baxter International Inc Baxter International Inc Valor: 911702
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.11%USD 18.31
COSMO Pharmaceuticals N.V.
COSMO Pharmaceuticals N.V. COSMO Pharmaceuticals N.V. Valor: 32590356
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.45%CHF 67.10
Astrana Health Inc
Astrana Health Inc Astrana Health Inc Valor: 28041888
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
10.62%USD 22.50
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA SCHOTT Pharma AG & Co. KGaA Valor: 128964250
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.66%EUR 18.44
Coloplast A/S
Coloplast A/S Coloplast A/S Valor: 20259063
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.55%DKK 580.20